ArticleAdvances in nutrition (Bethesda, Md.)2019
Protective Effects of Epigallocatechin-3-Gallate from Green Tea in Various Kidney Diseases.
Article in Advances in nutrition (Bethesda, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Potential Therapeutic Effects of Natural Plant Compounds in Kidney Disease.Molecules (Basel, Switzerland) · 2021Pooled it
- Tea and coffee consumption and the risk of urinary stones-a systematic review of the epidemiological data.World journal of urology · 2021Pooled it
- Tea and coffee consumption and pathophysiology related to kidney stone formation: a systematic review.World journal of urology · 2021Pooled it
- Decaffeinated green tea polyphenols supplementation had no adverse health effects in girls with obesity: a randomized controlled trial.Asia Pacific journal of clinical nutrition · 2024Trial
- Allicin inhibits kidney stone formation by suppressing the TNF/NF-κB pathway: Experimental validation through network pharmacology, in vitro, and in vivo studies.Molecular biology reports · 2026Article
- Natural compounds targeting inflammatory signaling and cell adhesion molecules in ischemic acute kidney injury.Archives of pharmacal research · 2026Review
- Systematic evaluation and comparison of theCurrent research in food science · 2026Article
- NRF2 Dysregulation and Therapeutic Insights Across Chronic Kidney Diseases.International journal of molecular sciences · 2025Review
- Bioactive Compound-Fortified Nanomedicine in the Modulation of Reactive Oxygen Species and Enhancement of the Wound Healing Process: A Review.Pharmaceutics · 2025Review
- Cardioprotective and Anti-Hypertensive Effects of Epigallocatechin Gallate: Novel Insights Into Biological Evidence.Journal of clinical hypertension (Greenwich, Conn.) · 2025Review
- Epigallocatechin-3-Gallate (EGCG)-Loaded Hyaluronic Acid Hydrogel Seems to Be Effective in a Rat Model of Collagenase-Induced Achilles Tendinopathy.Journal of functional biomaterials · 2025Article
- Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease.Nature reviews. Nephrology · 2025Review
- EGCG alleviates PM2.5-induced lung injury via activation of PPAR-γ to suppress inflammation and oxidative stress.Frontiers in pharmacology · 2025Article
- Epigallocatechin Gallate Attenuates CaOx Crystal-Induced Renal Tubular Injury to Inhibit CaOx Nephrolithiasis via GRP94/PI3K/AKT Signaling.Biomaterials research · 2025Article
- The Potential of Naturally Derived Compounds for Treating Chronic Kidney Disease: A Review of Autophagy and Cellular Senescence.International journal of molecular sciences · 2024Review
- Alleviation effects of epigallocatechin-3-gallate against acute kidney injury following severe burns.Clinical and experimental nephrology · 2024Article
- Article
- Erythrocyte membrane biomimetic EGCG nanoparticles attenuate renal injury induced by diquat through the NF-κB/NLRP3 inflammasome pathway.Frontiers in pharmacology · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney diseases are common health problems worldwide. Various etiologies (e.g., diabetes, hypertension, drug-induced nephrotoxicity, infection, cancers) can affect renal function and ultimately lead to development of chronic kidney disease (CKD) and end-stage renal disease (ESRD). The global rise in number of CKD/ESRD patients during recent years has led to tremendous concern to look for effective strategies to prevent or slow progression of CKD and ESRD. Natural compounds derived from herbs or medicinal plants have gained wide attention for scientific scrutiny to achieve such goals. One of such natural compounds that has been extensively investigated is epigallocatechin-3-gallate (EGCG), a major polyphenol found in the tea plant (Camellia sinensis). A growing body of recent evidence has shown that EGCG may be a promising therapeutic or protective agent in various kidney diseases. This article thus highlights recent progress in medical research on beneficial effects of EGCG against a broad spectrum of kidney diseases, including acute kidney injury, cisplatin-induced nephrotoxicity, kidney stone disease, glomerulonephritis, lupus nephritis, renal cell carcinoma, diabetic nephropathy, CKD, and renal fibrosis. The renoprotective mechanisms are also detailed. Finally, future perspectives of medical research on EGCG and its potential use in clinical practice for treatment and prevention of kidney diseases are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.